No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...